Here's a clear and structured comparison of the three major pharmacopoeias — Indian

Pharmacopoeia (IP), British Pharmacopoeia (BP), and United States Pharmacopeia (USP)
— perfect for a college/school assignment.

United States
Indian Pharmacopoeia British
Parameter Pharmacopeia (USP–
(IP) Pharmacopoeia (BP)
NF)
British
United States
Indian Pharmacopoeia Pharmacopoeial
Pharmacopeial
Commission (IPC), Commission
Convention (USP) – an
Published by Ministry of Health & (Secretariat: MHRA –
independent, non-
Family Welfare, Govt. of Medicines and
governmental
India Healthcare products
organization
Regulatory Agency)
First Edition 1955 1864 1820
Latest Edition (as of IP 2022 (9th Edition) + BP 2025 (effective USP 48–NF 43 (effective
Nov 2025) Addendum 2023 & 2024 from 1 Jan 2025) from May 1, 2025)
Legal standard in UK
Legal under Drugs and
and recognized in Legally enforceable in
Cosmetics Act, 1940
over 100 countries USA under FD&C Act;
Legal Status (India) – mandatory for
(including many also widely accepted
drugs manufactured/sold
Commonwealth globally
in India
nations)
Standards for drugs, Drugs, excipients,
Drugs, excipients, dietary
excipients, dosage forms, herbals, biologicals,
supplements, biologics,
Scope biologicals, medical blood products used
medical devices in the
devices, etc., marketed in in UK and many other
USA
India countries
>5,000 drug monographs
~3,000+ monographs (IP
Monographs ~4,000+ monographs + >300 dietary
2022)
supplements
Numbered <1> to <1> to <2000+ (includes
<1 to <200 series
General Chapters <400+ (harmonized many harmonized
(similar to BP/USP)
with Ph. Eur.) chapters)
Closely aligned with
USP–NF (National
European
Formulary) is published
Related Official None (but aligns with Pharmacopoeia (Ph.
together; USP also
Compendium BP, USP, Ph. Eur.) Eur.) – BP includes
harmonizes with Ph. Eur.
all Ph. Eur.
& JP via PDG
monographs
Participates in Full member of PDG; Full member of PDG;
Pharmacopoeial almost 100% many
Harmonization
Discussion Group (PDG) harmonized with Ph. chapters/monographs
with Ph. Eur., USP, JP Eur. harmonized
Biological Products Separate volume (IP Extensive biological Extensive in USP and
 United States
Indian Pharmacopoeia British
Parameter Pharmacopeia (USP–
(IP) Pharmacopoeia (BP)
NF)
Biologics) under
monographs (aligned separate USP Biologics
development; some
with Ph. Eur.) chapters
monographs in main IP
Indian Pharmacopoeia
British
includes Ayurvedic,
Pharmacopoeia Dietary supplements and
Traditional/Herbal Siddha, Unani
Herbal (BPH) and some botanicals in USP–
Medicines monographs in separate
Traditional Herbal NF
volumes (e.g., Ayurvedic
Medicines
Pharmacopoeia of India)
UV, IR, HPLC, GC,
Same modern techniques;
TLC, Dissolution, Same as Ph. Eur.
Testing Methods many identical to BP/Ph.
Microbial limits, etc. (highly harmonized)
Eur.
(largely harmonized)
BP Chemical
Reference IP Reference Standards USP Reference Standards
Reference Substances
Standards (IPRS) supplied by IPC (highly pure)
(BPCRS)
Frequency of New edition every 4–5 Annual edition Annual edition (usually
Updates years + annual addenda (effective 1 January) effective May 1)
Print + online (paid Online (free in UK via Online (some sections
Availability subscription via MHRA; paid free) + print
[Link]) elsewhere) + print (subscription-based)

Key Points for Assignment

1. Oldest: USP (1820) → BP (1864) → IP (1955)

2. Most globally influential: USP and BP/Ph. Eur. (because of FDA and EMA acceptance)
3. India-specific: IP is mandatory in India, but many multinational companies follow both
IP and USP/BP for export markets.
4. Harmonization efforts: Through PDG (Ph. Eur., BP, USP, JP), more than 60 general
chapters and many excipient monographs are now identical or very similar.
5. For export from India:
o To USA → USP compliance required
o To Europe/UK → Ph. Eur./BP compliance required
o Domestic market → IP compliance sufficient

Slide 1 – Title Slide

Title: Comparison of Indian Pharmacopoeia (IP), British Pharmacopoeia (BP) & United States
Pharmacopeia (USP-NF) Subtitle: Assignment Presentation Your Name | Roll No. | Class |
College Name Date: November 2025

Slide 2 – Introduction

 Pharmacopoeia = Official compendium containing standards for identity, strength,

quality & purity of medicines
 Three major pharmacopoeias widely used globally:
o Indian Pharmacopoeia (IP)
o British Pharmacopoeia (BP)
o United States Pharmacopeia (USP-NF)

Slide 3 – Basic Information Table (Part 1)

United States
Indian Pharmacopoeia British Pharmacopoeia
Parameter Pharmacopeia (USP-
(IP) (BP)
NF)
United States
Indian Pharmacopoeia British Pharmacopoeial
Published by Pharmacopeial
Commission Commission (MHRA)
Convention
First Edition 1955 1864 1820
Latest Edition USP 48–NF 43 (May
IP 2022 + Addendum 2024 BP 2025 (Jan 2025)
(2025) 2025)
Mandatory in India (Drugs Legal in UK & >100 Enforceable in USA
Legal Status
& Cosmetics Act) countries (FD&C Act)

Slide 4 – Basic Information Table (Part 2)

| Scope | Drugs, biologics, medical devices in India | Drugs, herbals, biologics (UK &
Commonwealth) | Drugs, supplements, biologics (USA) | | Total Monographs | ~3,000+ |
~4,000+ | >5,000 drugs + 300+ supplements | | Reference Standards | IPRS | BPCRS | USP
Reference Standards | | Update Frequency | Every 4–5 years + annual addenda | Annual (January)
| Annual (usually May) |

Slide 5 – Harmonization & Global Acceptance

 Pharmacopoeial Discussion Group (PDG): Ph. Eur. + BP + USP + JP

 More than 60 general chapters fully harmonized
 Excipient monographs largely identical
 For Indian manufacturers:
o Domestic market → IP sufficient
o Export to USA → Must comply with USP
o Export to Europe/UK → Must comply with Ph. Eur./BP
Slide 6 – Special Features

Feature IP BP USP-NF
Traditional Ayurvedic, Siddha, Unani British Pharmacopoeia Dietary supplements &
Medicines (separate volumes) Herbal (BPH) botanicals
Developing separate IP- Extensive (aligned with
Biological Products Very comprehensive
Biologics Ph. Eur.)
European
Closely Related National Formulary
— Pharmacopoeia (Ph.
Compendium (NF)
Eur.)

Slide 7 – Oldest to Newest

1820 → USP (Oldest) 1864 → BP 1955 → IP (Newest among the three)

Slide 8 – Testing Methods (Common & Harmonized)

 UV, IR, HPLC, GC, TLC

 Dissolution apparatus (Type 1 & 2)
 Microbial limit tests
 Heavy metal tests → All three use almost identical modern methods due to PDG
harmonization

Slide 9 – Conclusion

 USP: Oldest, most comprehensive, globally dominant

 BP: Closely linked with European Pharmacopoeia
 IP: Mandatory in India, rapidly aligning with global standards
 Harmonization ensures same quality worldwide

Slide 10 – Thank You

References
Indian Pharmacopoeia 2022 & Addenda (ipc Slide 1 – Title Slide

Title: Comparison of Indian Pharmacopoeia (IP), British Pharmacopoeia (BP) and United States
Pharmacopeia (USP-NF) Subtitle: A Comprehensive Overview (2025) Your Name |
College/University | Date

Slide 2 – Introduction

 Pharmacopoeias = Official compendia containing standards for identity, strength, quality

& purity of medicines
 Essential for manufacturers, regulators, and quality control laboratories
 Today we compare the three major pharmacopoeias relevant to the Indian pharmaceutical
industry

Slide 3 – Overview Table (Part 1)

United States
Indian Pharmacopoeia British Pharmacopoeia
Parameter Pharmacopeia (USP–
(IP) (BP)
NF)
Indian Pharmacopoeia United States
British Pharmacopoeial
Published by Commission (IPC), Govt. Pharmacopeial
Commission (MHRA)
of India Convention (non-govt)
First Edition 1955 1864 1820
Latest Edition IP 2022 + Addendum 2023 BP 2025 (effective 1 Jan USP 48–NF 43 (effective
(Nov 2025) & 2024 2025) May 2025)
Enforceable in USA
Mandatory in India (Drugs Legal in UK + >100
Legal Status (FD&C Act) + global
& Cosmetics Act, 1940) countries
acceptance

Slide 4 – Overview Table (Part 2)

Parameter IP BP USP–NF
Drugs, excipients, Drugs, herbals, blood Drugs, dietary
Scope biologics, medical products (UK + supplements, biologics
devices (India) Commonwealth) (USA)
>5,000 drugs + >300
Monographs ~3,000+ ~4,000+
supplements
General <1> to <400+ (harmonized
<1> to <200 series <1> to <2000+
Chapters with Ph. Eur.)

Slide 5 – Harmonization & Related Compendia

 Related Compendia – IP: None (but aligns with global standards) – BP: BP = European
Pharmacopoeia (Ph. Eur.) + UK content – USP: Published with National Formulary (NF)
  Harmonization All three are members of Pharmacopoeial Discussion Group (PDG)
along with Japanese Pharmacopoeia (JP) → >60 general chapters & many excipient
monographs now identical

Slide 6 – Biologicals & Traditional Medicines

Area IP BP USP–NF
Biological Some monographs; separate Extensive (aligned with Extensive + separate
Products IP Biologics in progress Ph. Eur.) Biologics chapters
Traditional / Ayurvedic, Siddha, Unani British Pharmacopoeia Dietary supplements &
Herbal (separate volumes) Herbal (BPH) botanicals in NF

Slide 7 – Testing Methods & Reference Standards

 Testing Methods (largely harmonized across all three) UV, IR, HPLC, GC, TLC,
Dissolution, Microbial limits, etc.
 Reference Standards – IP → IPRS (Indian Pharmacopoeia Reference Standards) – BP
→ BPCRS – USP → USP Reference Standards (gold standard globally)

Slide 8 – Update Frequency & Availability

Feature IP BP USP–NF
Frequency of Every 4–5 years + Annual + supplements
Annual (Jan 1)
Updates annual addenda (bimonthly from 2026)
Paid online ([Link]) Free in UK; paid Some free sections;
Availability
+ print elsewhere subscription-based

Slide 9 – Timeline of First Editions

(Insert horizontal timeline graphic) 1820 ────────────────── USP (USA) 1864

───────────── BP (UK) 1955 ─── IP (India)

Slide 10 – Key Takeaways (1–5)

1. Oldest to newest: USP (1820) → BP (1864) → IP (1955)

2. Most globally influential: USP & BP/Ph. Eur. (accepted by FDA & EMA)
3. India context: IP mandatory domestically; export needs USP or BP/Ph. Eur. compliance
4. Strong harmonization via PDG → reduces duplication for manufacturers
5. Export from India: • USA → Must comply with USP • Europe/UK → Must comply with
Ph. Eur./BP • Domestic → IP is sufficient

Slide 11 – Practical Implications for Indian Pharma Industry

 Indian companies often maintain dual/triple compliance (IP + USP + Ph. Eur.) to access
global markets
  Largest exporter of generics → USP compliance is critical
 CDSCO increasingly pushing IP harmonization with ICH/PDG standards

Slide 12 – Thank You / References

 .[Link])
 British Pharmacopoeia 2025 ([Link])
 USP–NF 48 ([Link])
 WHO Guidelines on Pharmacopoeial Standards
 Pharmacopoeial Discussion Group (PDG) reports